- Home
- CGTX vs GOSS Comparison
CGTX vs GOSS Comparison
Compare CGTX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGTX | GOSS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.5M | 88.6M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CGTX | GOSS |
|---|---|---|
| Price | $1.31 | $0.36 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $3.33 | ★ $4.19 |
| AVG Volume (30 Days) | 1.0M | ★ 6.4M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.79 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $201.64 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.22 | $0.32 |
| 52 Week High | $3.83 | $3.87 |
Technical Indicators
Market Signals| Indicator | CGTX | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 35.95 |
| Support Level | $1.29 | $0.33 |
| Resistance Level | $1.54 | $0.47 |
| Average True Range (ATR) | 0.10 | 0.03 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 83.88 | 19.56 |
Price Performance
Historical ComparisonAbout CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).